(Q47916425)

English

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

scientific article published on 4 March 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

type 2 diabetes

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

E Ferrannini

1

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

L Seman

2

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

E Seewaldt-Becker

3

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

S Hantel

4

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

S Pinnetti

5

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

H J Woerle

6

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

publication date

4 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

15

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

8

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

721-728

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

Prevention and early detection of vascular complications of diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12081

21 January 2018

Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12081

21 January 2018

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12081

21 January 2018

Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12081

21 January 2018

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12081

21 January 2018

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12081

21 January 2018

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12081

21 January 2018

Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12081

21 January 2018

SGLT2 inhibition--a novel strategy for diabetes treatment

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12081

21 January 2018

Learning from glycosuria

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12081

21 January 2018

Mechanism by which metformin reduces glucose production in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12081

21 January 2018

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12081

21 January 2018

Identifiers

10.1111/DOM.12081

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23398530

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47916425&oldid=2175697303"